1 - 25 of
1,052
results
for author:"Kim D."
in Literature Citations
| Tissue-specific activities of an immune signaling module regulate physiological responses to pathogenic and nutritional bacteria in C. elegans. Shivers R.P., Kooistra T., Chu S.W., Pagano D.J., Kim D.H. Cell Host Microbe 6:321-330(2009) · Mapped (6) |
| Membrane type-1 matrix metalloprotease-independent activation of pro-matrix metalloprotease-2 by proprotein convertases. Koo B.H., Kim H.H., Park M.Y., Jeon O.H., Kim D.S. FEBS J. 276:6271-6284(2009) · Mapped (7) |
| Targeted disruption of stat3 reveals a major role for follicular stem cells in skin tumor initiation. Kim D.J., Kataoka K., Rao D., Kiguchi K., Cotsarelis G., Digiovanni J. Cancer Res. 69:7587-7594(2009) · Mapped (6) |
| Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Lauchle J.O., Kim D., Le D.T., Akagi K., Crone M., Krisman K., Warner K., Bonifas J.M., Li Q., Coakley K.M. et al. Nature 461:411-414(2009) · Mapped (4) |
| 15-Deoxy-delta 12, 14-prostaglandin J2 induces upregulation of multidrug resistance-associated protein 1 via Nrf2 activation in human breast cancer cells. Song N.Y., Kim D.H., Kim E.H., Na H.K., Surh Y.J. Ann. N. Y. Acad. Sci. 1171:210-216(2009) · Mapped (10) |
| Effects of 15-deoxy-delta 12, 14-prostaglandin J2 on the expression of p53 in MCF-7 cells. Kim D.H., Kim E.H., Na H.K., Surh Y.J. Ann. N. Y. Acad. Sci. 1171:202-209(2009) · Mapped (31) |
| Pleiotropic roles of calumenin (calu-1), a calcium-binding ER luminal protein, in Caenorhabditis elegans. Cho J.H., Song H.O., Singaravelu G., Sung H., Oh W.C., Kwon S., Kim d.o. H., Ahnn J. FEBS Lett. 583:3050-3056(2009) · Mapped (2) |
| The common exon 3 polymorphism of the growth hormone receptor (GHR) gene and the effect of growth hormone therapy on growth in Korean patients with Turner syndrome. Ko J.M., Kim J.M., Cheon C.K., Kim D.H., Lee D.Y., Cheong W.Y., Kim E.Y., Park M.J., Yoo H.W. Clin. Endocrinol. (Oxf) 0:0-0(2009) · Mapped (5) |
| Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Khodadoust M.S., Verhaegen M., Kappes F., Riveiro-Falkenbach E., Cigudosa J.C., Kim D.S., Chinnaiyan A.M., Markovitz D.M., Soengas M.S. Cancer Res. 69:6405-6413(2009) · Mapped (6) |
| Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. Hughes T., Saglio G., Branford S., Soverini S., Kim D.W., Muller M.C., Martinelli G., Cortes J., Beppu L., Gottardi E. et al. J. Clin. Oncol. 27:4204-4210(2009) · Mapped (40) |
| Multiple hTAF(II)31-binding motifs in the intrinsically unfolded transcriptional activation domain of VP16. Kim D.H., Lee S.H., Nam K.H., Chi S.W., Chang I., Han K.H. BMB Rep 42:411-417(2009) · Mapped (4) |
| Genetic associations of common deletion polymorphisms in families with Avellino corneal dystrophy. Park M., Kim D.J., Kim K.J., Hong C.B., Kim Y.J., Cheong H.S., Shin H.D., Lee E.J., Kim H.N., Chung H.W. et al. Biochem. Biophys. Res. Commun. 387:688-693(2009) · Mapped (20) |
| Analysis of microsatellite instability, protein expression and methylation status of hMLH1 and hMSH2 genes in gastric carcinomas. Gu M., Kim D., Bae Y., Choi J., Kim S., Song S. Hepatogastroenterology 56:899-904(2009) · Mapped (43) |
| Effectiveness of each Bethesda marker in defining microsatellite instability when screening for Lynch syndrome. Sinn D.H., Chang D.K., Kim Y.H., Rhee P.L., Kim J.J., Kim D.S., Park C.K., Kim J.W., Yun S.H., Lee W.Y. et al. Hepatogastroenterology 56:672-676(2009) · Mapped (43) |
| Genomic organization and mRNA expression of manganese superoxide dismutase (Mn-SOD) from Hemibarbus mylodon (Teleostei, Cypriniformes). Cho Y.S., Lee S.Y., Bang I.C., Kim D.S., Nam Y.K. Fish Shellfish Immunol. 27:571-576(2009) · UniProtKB (1) |
| Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small cell lung cancer. Song S.Y., Jeong S.Y., Park H.J., Park S.I., Kim D.K., Kim Y.H., Shin S.S., Lee S.W., Ahn S.D., Kim J.H. et al. Lung Cancer 0:0-0(2009) · Mapped (7) |
| Crystal structure of the TNF-alpha-Inducing protein (Tipalpha) from Helicobacter pylori: Insights into Its DNA-binding activity. Jang J.Y., Yoon H.J., Yoon J.Y., Kim H.S., Lee S.J., Kim K.H., Kim d.o. J., Jang S., Han B.G., Lee B.I. et al. J. Mol. Biol. 392:191-197(2009) · Mapped (1) |
| Differential expression of p63 isoforms in normal skin and hyperproliferative conditions. Kim S.Y., Cho H.J., Kim D.S., Choi H.R., Kwon S.B., Na J.I., Jeon H.C., Huh C.H., Youn S.W., Cho K.H. et al. J. Cutan. Pathol. 36:825-830(2009) · Mapped (4) |
| Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Kim D.H., Sriharsha L., Xu W., Kamel-Reid S., Liu X., Siminovitch K., Messner H.A., Lipton J.H. Clin. Cancer Res. 15:4750-4758(2009) · Mapped (31) |
| Regulatory mechanism of matrix metalloprotease-2 enzymatic activity by factor Xa and thrombin. Koo B.H., Park M.Y., Jeon O.H., Kim D.S. J. Biol. Chem. 284:23375-23385(2009) · Mapped (16) |
| ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity. Kim D.H., Lee J., Lee B., Lee J.W. Mol. Endocrinol. 23:1556-1562(2009) · Mapped (6) |
| Flavin-containing monooxygenase 1-catalysed N,N-dimethylamphetamine N-oxidation. Lee S.K., Kang M.J., Jin C., In M.K., Kim D.H., Yoo H.H. Xenobiotica 39:680-686(2009) · Mapped (4) |
| Functional genomics of adhesion, invasion, and mycelial formation in Schizosaccharomyces pombe. Dodgson J., Avula H., Hoe K.L., Kim D.U., Park H.O., Hayles J., Armstrong J. Eukaryotic Cell 8:1298-1306(2009) · Mapped (6) |
| Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations. Tran-Fadulu V., Pannu H., Kim D.H., Vick G.W., Lonsford C.M., Lafont A.L., Boccalandro C., Smart S., Peterson K.L., Hain J.Z. et al. J. Med. Genet. 46:607-613(2009) · Mapped (12) |
| Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone. Park S.E., Kang E.S., Kim D.H., Kim S.K., Lee J.H., Ahn C.W., Lee H.C., Cha B.S. Diabet. Med. 26:577-581(2009) · Mapped (10) |
